pharmaphorum

JULY 18, 2025

Skip to main content Friday 18 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes

pharmaphorum

JULY 17, 2025

Skip to main content Thursday 17 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Immunization

pharmaphorum

JULY 1, 2025

billion, expanding its pipeline with a potential first-in-class treatment for autoimmune diseases as well as adding a novel RNA delivery system to its portfolio. billion, expanding its pipeline with a potential first-in-class treatment for autoimmune diseases as well as adding a novel RNA delivery system to its portfolio.

Diabetes

pharmaphorum

JUNE 26, 2025

Skip to main content Thursday 26 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Vaccines

Pharmaceutical Technology

FEBRUARY 24, 2023

Retatrutide Overview Retatrutide (LY-3437943) is under development for the treatment of type 2 diabetes mellitus and obesity. Eli Lilly and Co Overview Eli Lilly and Co (Lilly) is a healthcare company that is engaged in the discovery, development, and marketing of human healthcare products.

Diabetes

Pharmaceutical Technology

MARCH 1, 2023

Molecular Partners overview Molecular Partners is a clinical-stage bio-pharmaceutical company that develops biological drugs. The company offers advanced small protein therapies such as abicipar, a designed ankyrin repeat protein-based anti-angiogenic drug developed for diabetic macular edema and wet age- macular degeneration.

Pharmaceutical Companies

Pharmaceutical Technology

MARCH 1, 2023

Molecular Partners overview Molecular Partners is a clinical-stage bio-pharmaceutical company that develops biological drugs. The company offers advanced small protein therapies such as abicipar, a designed ankyrin repeat protein-based anti-angiogenic drug developed for diabetic macular edema and wet age- macular degeneration.

Pharmaceutical Companies

European Pharmaceutical Review

APRIL 10, 2024

While this approach has shown to be safe and efficient in Clostridium difficile, the variability between donors may lead to random outcomes and responses in patients for immune-mediated diseases. Internet] Pharmaceutical Technology. Notably, from one donor to another, significant variations exist.

Immunization

European Pharmaceutical Review

NOVEMBER 9, 2023

TNF-alpha is an immune modulating cytokine whose dysregulation can lead to prolonged inflammatory responses and is known to drive disease in a range of autoimmune and inflammatory disorders. MYMD-1 has shown effectiveness in pre-clinical and clinical studies in regulating the immune system.

Drug Development

Pharmaceutical Technology

MAY 15, 2023

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies.

Diabetes

The Thyroid Pharmacist

OCTOBER 27, 2023

In one study, one gram of berberine per day lowered fasting blood sugar by 20 percent in people with diabetes, which is comparable to a commonly prescribed diabetes medication. [8] It also supports healthy detoxification and the immune system. 9] It can be used to treat gut infections, yeast overgrowth, and SIBO.

Health and Personal Care Stores

pharmaphorum

NOVEMBER 2, 2020

Predicting protein structures would typically be a time-consuming process, but now scientists can use technology to better analyse viruses, thus helping in the search for a vaccine that can trigger an immune response. Scientists are using AI to sift through existing literature on a disease and study its disease’s structure.

Vaccines

pharmaphorum

DECEMBER 6, 2022

In particular, the hopes are that the information provided by volunteers will allow researchers to develop new ways to prevent, detect, and treat diseases and health conditions, such as cancer, Alzheimer’s, heart disease, arthritis, diabetes, and strokes. This makes it difficult to diagnose MS early.

Medical Records

PharmaShots

MARCH 29, 2023

Shots: Drug patent expiry is when a patent granted to a pharmaceutical company for a particular drug expires, allowing other companies to produce and sell generic versions Like every other utility patent, pharmaceuticals also get market exclusivity of 20 years.

Biosimilars

PharmaShots

MAY 23, 2023

It has triple mutation within the viral genome that causes augmented and selective replication in cancer cells and enhances induction of antitumor immune response. BMS's subsidiary, Celgene Corporation, is a pharmaceutical company primarily focusing on developing cancer treatment immunotherapies.

Pharmaceutical Companies

The Thyroid Pharmacist

JULY 7, 2023

In the case that root causes can’t be found or eliminated, there are other strategies that can be used to modulate the immune response against the thyroid, that will be discussed in this article. The fourth action I’ll cover is taking advantage of immune modulation.

Immunization

pharmaphorum

AUGUST 13, 2020

Bourla made Pfizer’s manufacturing capabilities available to small biotech concerns and is in talks to make large quantities of other companies’ COVID-19 drug candidates. There are many other mega pharmaceutical companies in the kill-COVID game: Johnson & Johnson, Sanofi, AstraZeneca, GSK and Roche included.

Health and Personal Care Stores

Pharmacy Times

JUNE 27, 2025

4,5 DREAMM-7 In DREAMM-7, patients with RRMM who had received at least 1 prior line of therapy were randomized 1:1 to receive belantamab mafodotin plus bortezomib (Velcade; Millennium/Takeda and Janssen Pharmaceutical Companies) and dexamethasone (BVd) compared with daratumumab (Darzalex; Johnson & Johnson), bortezomib, and dexamethasone (DVd).

Pharmacy Technician

pharmaphorum

JULY 30, 2021

Unlike for other conditions where the only affected person is the patient themself (plus their family and loved ones), vaccine hesitancy can jeopardise public health by hindering herd immunity. In this day and age where many seek health information from Facebook groups, it is easy for “echo chambers”–communities of like-minded people–to form.

Vaccines

pharmaphorum

JUNE 18, 2025

Skip to main content Wednesday 18 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views (..)

Diabetes

pharmaphorum

JULY 22, 2025

Skip to main content Tuesday 22 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Vaccines

pharmaphorum

JULY 10, 2025

Skip to main content Thursday 10 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Vaccines